These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 9170521

  • 1. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].
    Akaza H, Miyanaga N, Tsukamoto T, Ishikawa S, Noguchi R, Ohtani M, Kawabe K, Kubota Y, Fujita K, Obata K, Hirao Y, Kotake T, Ohmori H, Kumazawa J, Koiso K.
    Gan To Kagaku Ryoho; 1997 May; 24(7):829-36. PubMed ID: 9170521
    [Abstract] [Full Text] [Related]

  • 2. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
    Akaza H, Miyanaga N, Tsukamoto T, Ishikawa S, Noguchi R, Ohtani M, Kawabe K, Kubota Y, Fujita K, Obata K, Hirao Y, Kotake T, Ohmori H, Kumazawa J, Koiso K.
    Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
    [Abstract] [Full Text] [Related]

  • 3. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A.
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [Abstract] [Full Text] [Related]

  • 4. [Clinical evaluation of urinary NMP22 (nuclear matrix protein 22) bladder chek in the detection of patients with bladder cancer].
    Kitsukawa S, Yamamoto Y, Hosoda S, Otsuru N, Matsumoto T, Matsumoto T, Aizawa T, Noda K, Ito T.
    Hinyokika Kiyo; 2006 Mar; 52(3):167-72. PubMed ID: 16617867
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
    Kibar Y, Goktas S, Kilic S, Yaman H, Onguru O, Peker AF.
    Ann Clin Lab Sci; 2006 Mar; 36(1):31-8. PubMed ID: 16501234
    [Abstract] [Full Text] [Related]

  • 6. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder.
    Menendez V, Filella X, Alcover JA, Molina R, Mallafre JM, Ballesta AM, Talbot-Wright R.
    Anticancer Res; 2000 Mar; 20(2B):1169-72. PubMed ID: 10810416
    [Abstract] [Full Text] [Related]

  • 7. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
    Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, Shariat SF.
    Cancer; 2006 Apr 15; 106(8):1701-7. PubMed ID: 16541433
    [Abstract] [Full Text] [Related]

  • 8. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A, Kumar R, Gupta NP.
    Jpn J Clin Oncol; 2006 Mar 15; 36(3):172-5. PubMed ID: 16520358
    [Abstract] [Full Text] [Related]

  • 9. [Clinical evaluation of urinary nuclear matrix protein 22 as a marker for bladder cancer].
    Kurokawa S, Morita T, Muraishi O, Tokue A.
    Hinyokika Kiyo; 2001 Apr 15; 47(4):247-50. PubMed ID: 11411098
    [Abstract] [Full Text] [Related]

  • 10. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
    Giannopoulos A, Manousakas T, Gounari A, Constantinides C, Choremi-Papadopoulou H, Dimopoulos C.
    J Urol; 2001 Aug 15; 166(2):470-5. PubMed ID: 11458049
    [Abstract] [Full Text] [Related]

  • 11. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
    Shariat SF, Casella R, Wians FH, Ashfaq R, Balko J, Sulser T, Gasser TC, Sagalowsky AI.
    Eur Urol; 2004 Mar 15; 45(3):304-13; author reply 313. PubMed ID: 15036675
    [Abstract] [Full Text] [Related]

  • 12. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C, Pandrangi L, Potts JM, Kursh E, Novick A, Agarwal A.
    Anticancer Res; 1999 Mar 15; 19(4A):2621-3. PubMed ID: 10470205
    [Abstract] [Full Text] [Related]

  • 13. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
    Moonen PM, Kiemeney LA, Witjes JA.
    Eur Urol; 2005 Dec 15; 48(6):951-6; discussion 956. PubMed ID: 16257108
    [Abstract] [Full Text] [Related]

  • 14. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF, Herman MP, Casella R, Lotan Y, Karam JA, Stenman UH.
    Eur Urol; 2005 Sep 15; 48(3):424-31. PubMed ID: 15963628
    [Abstract] [Full Text] [Related]

  • 15. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C, Pandrangi L, Agarwal A.
    J Urol; 1999 Jan 15; 161(1):62-5. PubMed ID: 10037369
    [Abstract] [Full Text] [Related]

  • 16. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
    Jamshidian H, Kor K, Djalali M.
    Urol J; 2008 Jan 15; 5(4):243-7. PubMed ID: 19101898
    [Abstract] [Full Text] [Related]

  • 17. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor.
    Casella R, Huber P, Blöchlinger A, Stoffel F, Dalquen P, Gasser TC, Lehmann K.
    J Urol; 2000 Dec 15; 164(6):1926-8. PubMed ID: 11061883
    [Abstract] [Full Text] [Related]

  • 18. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University.
    Kapila K, Kehinde EO, Anim JT, Mojiminiyi OA, Vinsu A, George SS, Al-Maghrebi M, Al-Mulla F.
    Cytopathology; 2008 Dec 15; 19(6):369-74. PubMed ID: 18631356
    [Abstract] [Full Text] [Related]

  • 19. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
    Song JW, DU LL, Zhao XW, Jing JX, Han CZ, Cui Y, Liu JW, Hao HL, Wang ZG, Mi ZG.
    Zhonghua Zhong Liu Za Zhi; 2009 Apr 15; 31(4):274-7. PubMed ID: 19615282
    [Abstract] [Full Text] [Related]

  • 20. Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis.
    Tritschler S, Scharf S, Karl A, Tilki D, Knuechel R, Hartmann A, Stief CG, Zaak D.
    Eur Urol; 2007 Feb 15; 51(2):403-7; discussion 407-8. PubMed ID: 16939699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.